Current trend in treatment of glioblastoma in Japan: a national survey using the diagnostic procedure combination database (J-ASPECT study-glioblastoma)

[1]  Y. Fujii,et al.  The Japan Neurosurgical Database: Overview and Results of the First-year Survey , 2020, Neurologia medico-chirurgica.

[2]  Satoshi O. Suzuki,et al.  First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide , 2020, Journal of neuro-oncology.

[3]  K. Hongo,et al.  The Influence of Age on the Outcomes of Traumatic Brain Injury: Findings from a Japanese Nationwide Survey (J-ASPECT Study-Traumatic Brain Injury). , 2019, World neurosurgery.

[4]  K. Houkin,et al.  The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in the patients with glioblastoma and anaplastic astrocytoma. , 2018, Journal of neurosurgical sciences.

[5]  S. Matsuda,et al.  Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin , 2018, Neurology.

[6]  S. Matsuda,et al.  Effect of treatment modality on in-hospital outcome in patients with subarachnoid hemorrhage: a nationwide study in Japan (J-ASPECT Study). , 2017, Journal of neurosurgery.

[7]  D. Osoba,et al.  Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma , 2017, The New England journal of medicine.

[8]  Satoshi O. Suzuki,et al.  Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status , 2017, OncoTargets and therapy.

[9]  K. Iihara,et al.  Current Trends and Healthcare Resource Usage in the Hospital Treatment of Primary Malignant Brain Tumor in Japan: A National Survey Using the Diagnostic Procedure Combination Database (J-ASPECT Study-Brain Tumor) , 2016, Neurologia medico-chirurgica.

[10]  S. Matsuda,et al.  Consciousness Level and Off‐Hour Admission Affect Discharge Outcome of Acute Stroke Patients: A J‐ASPECT Study , 2014, Journal of the American Heart Association.

[11]  S. Matsuda,et al.  Effects of Comprehensive Stroke Care Capabilities on In-Hospital Mortality of Patients with Ischemic and Hemorrhagic Stroke: J-ASPECT Study , 2014, PloS one.

[12]  S. Matsuda,et al.  The impact of comprehensive stroke care capacity on the hospital volume of stroke interventions: a nationwide study in Japan: J-ASPECT study. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[13]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[14]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[15]  Y. Imanaka,et al.  Effects of the per diem prospective payment system with DRG-like grouping system (DPC/PDPS) on resource usage and healthcare quality in Japan. , 2012, Health policy.

[16]  V. Rohde,et al.  First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience , 2010, Neurosurgical Review.

[17]  M. McGirt,et al.  Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. , 2009, Journal of neurosurgery.

[18]  Z. Ram,et al.  Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial , 2006, Acta Neurochirurgica.

[19]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[20]  Z. Ram,et al.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.

[21]  K. Arita,et al.  Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis. , 2017, Molecular and clinical oncology.

[22]  Yi-Hua Zhang,et al.  Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review. , 2014, Turkish neurosurgery.

[23]  F. Harrell,et al.  The National Neurosurgery Quality and Outcomes Database (N2QOD): general overview and pilot-year project description. , 2013, Neurosurgical focus.